# Signals Article on Putative Target P55089 for Ulcerative Colitis
Background
The protein encoded by the putative target P55089 has surfaced as a candidate of interest in the study of ulcerative colitis, a chronic inflammatory condition affecting the colon. Preliminary data suggest that P55089 may be involved in the inflammatory pathways associated with ulcerative colitis, indicating its potential as a therapeutic target. Given the multifactorial nature of ulcerative colitis, further investigation into the molecular mechanisms involving this protein is crucial for the development of innovative treatment approaches.Data-mining rationale
Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "ulcerative colitis" against 146 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P55089 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in ulcerative colitis and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P55089 in the context of ulcerative colitis. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in ulcerative colitis.Reasoning for further validation
To substantiate the potential role of P55089 in ulcerative colitis, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P55089, by quantitative PCR (qPCR) in an independent cohort of ulcerative colitis patients to confirm expression patterns. 3. Investigate the tissue specificity of P55089 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in colonic tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P55089 within known biological pathways related to inflammation and ulcerative colitis. 5. If validation is achieved, assess the druggability of P55089 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: P55089](https://www.uniprot.org/uniprot/P55089)
- [NCBI GEO Accession GDS:200151911](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200151911)
- [NCBI GEO Accession GDS:200236055](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200236055)
- [NCBI GEO Accession GDS:200242140](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200242140)
- [NCBI GEO Accession GDS:200254312](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200254312)
- [NCBI GEO Accession GDS:200206171](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200206171)